Perspective Therapeutics Inc (AMEX: CATX) is -64.85% lower on its value in year-to-date trading and has touched a low of $1.60 and a high of $16.55 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CATX stock was last observed hovering at around $3.81 in the last trading session, with the day’s loss setting it -2.72%.
Currently trading at $1.09M, the stock is 9.60% and 31.69% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.13 million and changing 1133513% at the moment leaves the stock -32.87% off its SMA200. CATX registered 13.48% gain for a year compared to 6-month loss of 27.02%. The firm has a 50-day simple moving average (SMA 50) of $2.7488 and a 200-day simple moving average (SMA200) of $5.3922.
The stock witnessed a 50.83% gain in the last 1 month and extending the period to 3 months gives it a 59.47%, and is 4.93% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.34% over the week and 13.76% over the month.
Perspective Therapeutics Inc (CATX) has around 140 employees, a market worth around $268.71M and $1.47M in sales. Profit margin for the company is -5790.07%. Distance from 52-week low is 126.25% and -78.13% from its 52-week high. The company has generated returns on investments over the last 12 months (-29.63%).
The EPS is expected to grow by 6.46% this year
151.0 institutions hold shares in Perspective Therapeutics Inc (CATX), with institutional investors hold 75.33% of the company’s shares. The shares outstanding are 74.05M, and float is at 54.14M with Short Float at 10.37%. Institutions hold 61.15% of the Float.
Perspective Therapeutics Inc (CATX) Insider Activity
The most recent transaction is an insider purchase by Spoor Johan M., the company’s Chief Executive Officer. SEC filings show that Spoor Johan M. bought 22,026 shares of the company’s common stock on Mar 28 ’25 at a price of $2.24 per share for a total of $49384.0. Following the purchase, the insider now owns 59383.0 shares.
Perspective Therapeutics Inc disclosed in a document filed with the SEC on Mar 28 ’25 that Spoor Johan M. (Chief Executive Officer) bought a total of 4,650 shares of the company’s common stock. The trade occurred on Mar 28 ’25 and was made at $2.21 per share for $10288.0. Following the transaction, the insider now directly holds 4650.0 shares of the CATX stock.
Still, SEC filings show that on Mar 31 ’25, Williamson Robert F III (Director) acquired 38,145 shares at an average price of $2.14 for $81775.0. The insider now directly holds 108,982 shares of Perspective Therapeutics Inc (CATX).
